Campaign launched to combat male infertility
Hyderabad: Oasis Fertility has launched a unique initiative, 'Happy Father's-To-Be Day' to celebrate the spirit of Fatherhood with a theme, 'Healthy Man, Father'. The event was inaugurated by the Chief Guest A Ramulu, Additional DCP, Hyderabad Traffic Police alongside Dr Krishna Chaitanya M, Scientific Head and Clinical Embryologist, Oasis Fertility, and other dignitaries.
In this regard, under the empowering theme 'Healthy Man, Happy Father', Oasis Fertility celebrates the journey of men aspiring to fatherhood through its campaign. This initiative is a step toward breaking the silence around male infertility, challenging long-held stigmas, and ensuring men have access to personalised, research-driven fertility treatments. As part of the initiative, Oasis Fertility offered free semen analysis for traffic police personnel, along with free fertility screening assessments across all its centres in Telangana on the June 14.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 days ago
- Time of India
Male fertility: The unsung half of the parenthood journey
Representative Image Becoming a parent is one of life's most profound and cherished milestones. Yet, in many traditional societies like India, discussions around fertility tend to focus predominantly on motherhood, often sidelining the role of fatherhood. Oasis Fertility , through the insights of Dr Krishna Chaitanya Mantravadi, Scientific Head , highlights that parenthood is a shared responsibility where male reproductive health is just as vital in the journey to conception. Despite this, the persistent myth that infertility is solely a woman's issue continues to blur the truth. Infertility is on the rise across India, particularly in states like Telangana, where around 15% of couples are affected. Nationally, an estimated 15–20 million couples grapple with infertility, with male factors contributing to nearly 40–45% of cases. 1 However, due to deep-seated stigma, misconceptions, and ignorance, men are less likely to seek help or even acknowledge the issue. Misconceptions such as 'age doesn't affect male fertility' or 'conception is easy post-marriage' only add to the problem. 'Male infertility can stem from a variety of causes, primarily categorised under sperm disorders, hormonal imbalances, and lifestyle factors. Early diagnosis significantly improves the chances of conception. Unfortunately, many men delay treatment due to stigma, misinformation, or denial. This not only reduces success rates but can also lead to emotional and financial strain. The good news is that most male infertility conditions are treatable, and advanced reproductive technologies have opened doors even in complex cases.', affirms Dr Krishna Chaitanya M, Scientific Head, Oasis Fertility . The most common issues include: Sperm disorders: These involve low sperm count (oligospermia), absence of sperm (azoospermia), poor sperm motility (asthenospermia), and abnormal shape or morphology (teratospermia). These are the most prevalent causes of male infertility. Varicocele : A prevalent disorder characterised by enlargement of the veins draining the testicle. Varicocele is the most common reversible cause of male infertility. Ejaculation issues: These range from retrograde ejaculation—where semen enters the bladder during orgasm instead of exiting the penis, to premature ejaculation and erectile dysfunction. They can result from diabetes, spinal injuries, certain medications, or past surgeries. Infections: Conditions such as gonorrhoea, HIV, and other STIs, as well as orchitis (testicle inflammation) and epididymitis (epididymis inflammation), can impair sperm production or block sperm transport. Hormonal imbalances: Disorders affecting testosterone, luteinising hormone (LH), or follicle-stimulating hormone (FSH) can disrupt sperm production and overall reproductive function. Lifestyle factors: Smoking, excessive alcohol consumption, drug use, obesity, sedentary habits, poor diet, and exposure to environmental toxins or heat can all reduce sperm count and quality. Several IVF clinics and medical organisations are breaking the stigma around male infertility, urging men to seek scientific treatments and highlighting the vital role of male reproductive health in ensuring healthy offspring. Modern treatment options include: Intracytoplasmic Sperm Injection ( ICSI ): A single sperm is injected directly into the egg to aid fertilisation. Testicular Sperm Extraction (TESE): A surgical procedure to retrieve sperm in cases of azoospermia. DNA Fragmentation Tests: Assess the quality of sperm DNA, especially useful for couples with repeated IVF failures or miscarriages. With the help of customised treatment protocols and cutting-edge techniques, many men with fertility issues can now realise their dream of fatherhood. Among the organisations leading the charge in addressing male infertility is Oasis Fertility —a pioneer in ethical, technology-driven fertility care. With over 31 advanced centres in 19 Indian cities, Oasis Fertility boasts an impressive IVF success rate of 65%, surpassing global benchmarks. Backed by an expert medical team and advanced infrastructure, the centre has helped welcome over 100,000 healthy babies into the world. What sets Oasis apart is its scientific methods, transparent practices, accessible pricing, compassionate care and personalised treatment plans. Clinics also operate during evenings and Sundays, catering to the schedules of working professionals. In celebration of Father's Day, Oasis Fertility has launched a powerful initiative titled 'Happy Fathers-to-Be', centred on the theme 'Healthy Man, Happy Father.' This campaign aims to encourage men to participate actively in the fertility journey by offering personalised counselling and comprehensive support covering medical, nutritional, and lifestyle aspects. As part of the campaign, Oasis Fertility offered free semen analysis for traffic police personnel, along with free fertility screening assessments across all its centres in Telangana on June 13th. Additionally, the campaign features interactive educational workshops and personalised counselling sessions designed to dispel common myths about male infertility and raise awareness about key contributing factors such as age, poor diet, stress, sleep, exposure to environmental toxins, and excessive use of digital devices, encouraging men to take proactive steps toward improving their fertility and overall well-being. By focusing on both physical and emotional well-being, the campaign helps men understand the importance of early screening, proper diagnosis, and evidence-based treatment. Redefining fatherhood Male infertility is no longer a hidden or silent issue. By integrating healthy lifestyle practices, embracing scientific advancements, and seeking timely medical help, men can significantly improve their fertility and support their partners on the journey to parenthood. Campaigns such as 'Happy Fathers-to-be-day' encourage men to incorporate fertility treatments and take an active role in their reproductive journeys. This Fathers' Day, let's honour fatherhood and put the health and wellbeing of soon-to-be fathers first, redefining what it means to be a father. TIL does not take any responsibility for the accuracy of their views. This should not be considered a substitute for medical advice. Please consult your treating physician for more details. This article has been produced on behalf of Roche by Times Internet's Spotlight team.
India Today
5 days ago
- India Today
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%.The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country."'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous The material and information contained are for advertorial purposes only. India Today holds no responsibility for the content written on the website as a basis for making any business, legal, or any other decision. Any reliance placed on such material is at your own risk.- Ends advertisement
Hans India
21-06-2025
- Hans India
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve repair. Meril is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac care. MyClip TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%. The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the procedure. According to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger demographics. The launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.
